Review
Immunology
Tao Zhang, Cunzheng Zhang, Jindong Zhang, Feng Sun, Liping Duan
Summary: This network meta-analysis found that B.coagulans exhibited significant efficacy in treating IBS patients, L.plantarum ranked first in improving quality of life, and L.acidophilus had the lowest incidence of adverse events. Treatment length significantly influenced the efficacy of probiotics in improving abdominal pain and straining.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2022)
Review
Gastroenterology & Hepatology
Vivek C. Goodoory, Mais Khasawneh, Christopher J. Black, Eamonn M. M. Quigley, Paul Moayyedi, Alexander C. Ford
Summary: This article conducted a meta-analysis to study the efficacy of probiotics in the treatment of irritable bowel syndrome (IBS). The study found that certain combinations of probiotics or strains may be beneficial for IBS, but the certainty of the evidence was low.
Review
Medicine, General & Internal
Fei Yao, Xutao Wu, Huacheng Zhao, Chun Gan
Summary: This study aims to resolve the uncertainty regarding the effectiveness of psychological interventions for irritable bowel syndrome (IBS) through systematic review and meta-analysis. It provides a comprehensive analysis of the existing evidence to inform practitioners and policy makers.
Review
Gastroenterology & Hepatology
Maria Rosa Ingrosso, Gianluca Ianiro, Judy Nee, Anthony J. Lembo, Paul Moayyedi, Christopher J. Black, Alexander C. Ford
Summary: This study aimed to evaluate the efficacy and safety of peppermint oil in the treatment of IBS. The results showed that peppermint oil was more effective than placebo, but adverse events occurred more frequently.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Nutrition & Dietetics
Peiwei Xie, Mei Luo, Xuehong Deng, Jiahui Fan, Lishou Xiong
Summary: This network meta-analysis compared and ranked the efficacy of different probiotic strains or combinations in treating IBS. It found that certain probiotics were effective in improving specific symptoms of IBS. However, further studies are needed to confirm these results.
Review
Nutrition & Dietetics
Magdalena Mroz, Marcin Czub, Anna Brytek-Matera
Summary: Irritable bowel syndrome (IBS) is a functional and psychosomatic disease that reduces quality of life and increases the risk of mental disorders. The deregulation of the autonomic nervous system (ANS) is a major cause of the disease. This study aimed to evaluate the effectiveness of IBS therapy by measuring heart rate variability (HRV) before and after therapeutic interventions. The findings suggest that interventions such as ear acupressure, transcutaneous auricular vagus nerve stimulation, cognitive behavioral therapy with relaxation elements, and yoga can improve ANS efficiency and reduce IBS symptoms.
Review
Medicine, General & Internal
Cristian-Ioan Babos, Daniel-Corneliu Leucuta, Dan Lucian Dumitrascu
Summary: This study assessed the effectiveness of meditation/mindfulness in improving symptoms severity, quality of life, and other associated mental conditions in patients with irritable bowel syndrome (IBS). The meta-analysis results showed statistically significant improvements in symptom score, quality of life, spiritual scale, and pain score in the mindfulness group compared to the control group.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Chao-Rong Xie, Bin Tang, Yun-Zhou Shi, Wen-Yan Peng, Kun Ye, Qing-Feng Tao, Shu-Guang Yu, Hui Zheng, Min Chen
Summary: This study evaluated the most effective approaches for managing irritable bowel syndrome (IBS) by analyzing different combinations and components of probiotics or a low FODMAP diet. The results showed that Lactobacillus was the most effective component for relieving IBS symptoms, while Bifidobacterium and Bacillus were potentially effective and require further verification.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Medicine, General & Internal
Michelle Y. Nabi, Samal Nauhria, Morgan Reel, Simon Londono, Anisha Vasireddi, Mina Elmiry, Prakash V. A. K. Ramdass
Summary: The study aimed to estimate the pooled odds ratio of endometriosis and irritable bowel syndrome, and the pooled prevalence of irritable bowel syndrome in patients with endometriosis. The results showed that patients with endometriosis have a threefold increased risk of developing irritable bowel syndrome, and the prevalence of irritable bowel syndrome in women with endometriosis was 23.4%.
FRONTIERS IN MEDICINE
(2022)
Review
Medicine, General & Internal
Jialei Guo, Li Yang, Jing He, Zhengming Yang
Summary: This study conducted a network meta-analysis to evaluate the clinical efficacy of different acupuncture and moxibustion therapies in the treatment of IBS, aiming to provide a scientific basis for selecting the best treatment options for IBS patients.
Review
Medicine, General & Internal
Jaroslaw Daniluk, Ewa Malecka-Wojciesko, Barbara Skrzydlo-Radomanska, Grazyna Rydzewska
Summary: Mebeverine has shown significant efficacy in treating irritable bowel syndrome, particularly in reducing abdominal pain and improving related symptoms. It has a good safety profile with minimal adverse effects.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Nutrition & Dietetics
Hangkai Huang, Linjie Lu, Yishu Chen, Yan Zeng, Chengfu Xu
Summary: This systematic review and meta-analysis explored the efficacy of vitamin D supplementation in patients with irritable bowel syndrome (IBS). The results indicated that vitamin D supplementation was superior to placebo in improving IBS symptoms and quality of life.
Review
Nutrition & Dietetics
Anne-Sophie van Lanen, Angelika de Bree, Arno Greyling
Summary: The low-FODMAP diet is effective in reducing symptoms severity and improving quality of life in patients with irritable bowel syndrome, regardless of age, intervention duration, and IBS subtype. Future research should focus on the long-term effects of such diets on nutritional adequacy and the gut microbiome.
EUROPEAN JOURNAL OF NUTRITION
(2021)
Review
Gastroenterology & Hepatology
Christopher J. Black, Heidi M. Staudacher, Alexander C. Ford
Summary: A low FODMAP diet is highly effective in treating IBS, showing significant improvement in global IBS symptoms and individual symptoms, particularly in reducing abdominal pain and bloating.
Review
Medicine, General & Internal
Xia Li, Bo Li, Jiaqi Zhang, Ting Chen, Haomeng Wu, Xiaoshuang Shi, Jinxin Ma, Jinyan Qin, Xudong Tang, Fengyun Wang
Summary: Irritable bowel syndrome (IBS) is a common gastrointestinal disease, and opioid receptor modulators have shown benefits in improving IBS symptoms, with eluxadoline being more effective in global symptoms and abdominal pain. However, the current evidence is limited, and future studies need to further evaluate long-term safety.
Review
Gastroenterology & Hepatology
Brigida Barberio, David J. Gracie, Christopher J. Black, Alexander C. Ford
Summary: This study conducted a network meta-analysis to compare the relative efficacy of various biological therapies and small molecules in the treatment of luminal Crohn's disease. The results showed differences in the effectiveness of different drugs in inducing and maintaining clinical remission, and previous exposure to biologics also had an impact on treatment outcomes.
Editorial Material
Gastroenterology & Hepatology
Eamonn M. M. Quigley, Alex Stevenson, Ian Jeffery, Jacob Masters
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Eamonn M. M. Quigley, Louise Markinson, Alex Stevenson, F. Peter Treasure, Brian E. Lacy
Summary: MRx1234 has the potential to become a novel, safe treatment option for patients with IBS-C or IBS-D, and for those who have mixed symptoms or transition between subtypes.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Vivek C. Goodoory, Cho E. Ng, Christopher J. Black, Alexander C. Ford
Summary: This study compared the characteristics of individuals with irritable bowel syndrome (IBS) reporting faecal incontinence (FI) with those who do not report FI. The results showed that individuals with FI were older, more likely to have IBS-D, had lower education levels and incomes, reported more urgency and more severe IBS and psychological symptoms, had lower quality of life scores, and higher healthcare costs.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Kee-Huat Chuah, Christopher J. Black, Vincent Tee, Sze-Zee Lim, Wen-Xuan Hian, Nur-Fazimah Sahran, Yeong-Yeh Lee, Sanjiv Mahadeva, Alexander C. Ford
Summary: By comparing IBS patients from the UK and Malaysia, it was found that UK patients were more likely to consume alcohol, had more frequent symptoms such as pain, bloating, and meal-related issues, higher symptom scores, greater limitation of activities, and a higher likelihood of reporting abnormal anxiety. UK patients also had higher levels of perceived stress, gastrointestinal symptom-specific anxiety, and somatoform symptom-reporting.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Editorial Material
Gastroenterology & Hepatology
Vivek C. Goodoory, Cho Ee Ng, Christopher J. Black, Alexander C. Ford
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Letter
Gastroenterology & Hepatology
Vivek C. Goodoory, Elspeth A. Guthrie, Cho Ee Ng, Christopher J. Black, Alexander C. Ford
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Gastroenterology & Hepatology
Mais Khasawneh, Orla F. Craig, David J. Gracie, Christopher J. Black, Alexander C. Ford
Summary: The study suggests that diagnosing IBS according to the Rome IV criteria and conducting limited investigation is safe and durable. Among IBS patients, although 1 in 6 were referred again due to gastrointestinal symptoms, missed organic gastrointestinal disease occurred in only 1% of patients.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Christy Riggott, Keeley M. Fairbrass, Christopher J. Black, David J. Gracie, Alexander C. Ford
Summary: Using latent class analysis, this study identified novel clusters of patients with inflammatory bowel disease (IBD) and found that patients with higher gastrointestinal and psychological symptoms were at a higher risk of adverse disease outcomes and were also high-volume users of healthcare.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Gastroenterology & Hepatology
Vivek C. Goodoory, Mais Khasawneh, Christopher J. Black, Eamonn M. M. Quigley, Paul Moayyedi, Alexander C. Ford
Summary: This article conducted a meta-analysis to study the efficacy of probiotics in the treatment of irritable bowel syndrome (IBS). The study found that certain combinations of probiotics or strains may be beneficial for IBS, but the certainty of the evidence was low.
Review
Gastroenterology & Hepatology
Pierfrancesco Visaggi, Brigida Barberio, Giulio Del Corso, Nicola de Bortoli, Christopher J. Black, Alexander C. Ford, Edoardo Savarino
Summary: A network meta-analysis was conducted to compare the efficacy of different drugs for active eosinophilic esophagitis (EoE). The results showed that most available drugs were more effective than placebo in treating EoE. However, significant heterogeneity among the trials hindered the establishment of a solid therapeutic hierarchy.
Article
Gastroenterology & Hepatology
Christy Riggott, Keeley M. Fairbrass, Christian P. Selinger, David J. Gracie, Alexander C. Ford
Summary: The use of opioids in patients with inflammatory bowel disease (IBD) is associated with psychological comorbidity and an increased risk of intestinal resection, particularly with stronger formulations. Future studies should classify the risks of different opioids to develop reliable prescribing algorithms, and evaluate the effectiveness of addressing psychological factors as an opioid avoidance strategy in routine IBD care.
INFLAMMATORY BOWEL DISEASES
(2023)
Review
Gastroenterology & Hepatology
Adam Saleh, Shyon Parsa, Manuel Garza, Eamonn M. M. Quigley, Bincy P. Abraham
Summary: Microbiome and/or microbiome-host immune system interactions play an important role in the pathogenesis of inflammatory bowel disease (IBD), leading to interest in microbiota-modulating interventions like fecal microbiota transplantation (FMT) for managing ulcerative colitis (UC). Studies have shown varying clinical responses to FMT in UC, but certain characteristics of the donor microbiome, such as increased biodiversity, specific bacteria, and reduced bacteriophages, predict a positive response. However, inconsistencies in FMT protocols and the need for further randomized controlled trials hinder its widespread recommendation as a treatment for UC.
DIGESTIVE DISEASES
(2023)
Article
Gastroenterology & Hepatology
Brigida Barberio, Keeley M. Fairbrass, David J. Gracie, Alexander C. Ford
Summary: In this 12-month longitudinal study, one-third of patients with IBD reported presence of Rome III IBS-type symptoms at any point in time. Reporting such symptoms was associated with significant impacts on psychological health and/or quality of life.
NEUROGASTROENTEROLOGY AND MOTILITY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Mais Khasawneh, Orla F. Craig, David J. Gracie, Christopher J. Black, Alexander C. Ford